Amphastar pharmaceuticals, inc. being investigated on behalf of amphastar pharmaceuticals, inc. investors. contact levi & korsinsky for details

New york, ny / access newswire / february 28, 2025 / levi & korsinsky notifies investors that it has commenced an investigation of amphastar pharmaceuticals, inc. ("amphastar pharmaceuticals, inc.") (nasdaq:amph) concerning possible violations of federal securities laws. on november 6, 2024, amphastar received a secondary complete response letter (crl) from the food and drug administration (fda) for its generic teriparatide anda, amp-015, following months of delays surrounding the submission of the drug.
AMPH Ratings Summary
AMPH Quant Ranking